Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03227588
Other study ID # 966635
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 10, 2017
Est. completion date December 10, 2019

Study information

Verified date February 2019
Source Central Arkansas Veterans Healthcare System
Contact Barry F. Uretsky, MD
Phone 501-257-1000
Email barry.uretsky@va.gov
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The use of fractional flow reserve (FFR) has improved outcomes in percutaneous coronary interventions (PCI) in patients with symptomatic stable coronary artery disease (CAD) with intermediate angiographic stenoses. It is a clinical tool used routinely in cardiac catheterization laboratories throughout the world including the Little Rock VA Hospital. The technique utilizes a pressure transducer constructed as part of an 0.014" guidewire. An FFR of >0.80 has been linked with myocardial ischemia found with nuclear stress and dobutamine echo stress testing. The FAME trial clearly demonstrated its value in improving long-term outcomes as compared to use of angiography alone. As such, the use of FFR is incorporated into both AHA ACC and European PCI guideline recommendations as part of routine care for intermediate lesions. A "work horse" guide wire is so defined because it can be used in most PCI cases. It combines a low tip load (to avoid intimal dissection, with excellent (ideally, one to one) torque transmission and trackability through tortuous lesions. Recently the FDA has approved an FFR guide wire, OptoWire, (Opsens, Quebec City, Quebec, CAN) which uses light transmission to measure pressure rather than electrical transduction wires. The primary purpose of the present study is to determine how effective this wire is as a work horse wire in patients in whom FFR is required. The OptoWire may also have the advantage of less "drift" occurring during the procedure. Drift refers to the change in pressure due to issues related to the wire and measuring system, rather than a true change in pressure. All current FFR wire systems demonstrate some degree of drift requiring measuring pressure of the wire in the aorta after the procedure is completed to determine if, and to what extent, drift has occurred. Thus, a secondary aim of this study will determine the degree of drift.


Description:

EVALUATION OF THE OPSENS FRACTIONAL FLOW RESERVE (FFR) WIRE AS A "WORK HORSE" WIRE

INVESTIGATORS:

PRINCIPAL INVESTIGATOR: BARRY F URETSKY, MD CO-INVESTIGATOR: ABDUL HAKEEM, MD CO-INVESTIGATOR: MALEK AL-HAWWAS, MD

Introduction The use of fractional flow reserve (FFR) has improved outcomes in percutaneous coronary interventions (PCI) in patients with symptomatic stable coronary artery disease (CAD) with intermediate angiographic stenoses. It is a clinical tool used routinely in cardiac catheterization laboratories throughout the world including the Little Rock VA hospital. The technique utilizes a pressure transducer constructed as part of an 0.014" guidewire. The wire is passed distal to the stenosis. Under the condition of maximal hyperemia induced by a drug, typically adenosine, the pressure proximal to the stenosis, i.e. aortic pressure or Pa and the pressure distal to the stenosis, Pd, are measured. The ratio, Pd/Pa, under maximal flow or hyperemia is known as the fractional flow reserve (FFR). An FFR of <0.80 has been correlated with observed myocardial ischemia using other diagnostic methods, particularly nuclear stress and dobutamine echo stress testing. The FAME trial clearly demonstrated its value in improving long-term outcomes as compared to use of angiography alone (1). As such, the use of FFR is incorporated into both AHA ACC and European PCI guideline recommendations as part of routine care for intermediate lesions (2,3).

One of the limitations of the use of the FFR pressure wire itself is that its handling characteristics are somewhat inferior to a standard "work horse" guide wire used for PCI. A "work horse" guide wire is so defined because it can be used in most PCI cases. It combines a low tip load (to avoid intimal dissection) with excellent (ideally, one-to-one) torque transmission and trackability through tortuous lesions. There are several different work horse wires available. Although the wires may be different for different Cath Labs and operators, the wires are universally used to maximize safety, efficacy, and efficiency of PCI.

In patients specifically requiring FFR to determine the value of PCI, it would be ideal if an FFR wire was as effective as a work horse wire so it could be used in difficult-to-traverse lesions. However, due to the complex electronics within current FFR wires, handling characteristics of previously used wires are inferior to current work horse wires. Recently the FDA has approved an FFR guide wire, OptoWire, (Opsens, Quebec City, Quebec, CAN) using light transmission to measure pressure rather than electrical transduction (4). It is commercially available in the United States. Its handling characteristics appear to approach that of a work horse guide wire and may represent an improvement over electrical transduction wires. The primary purpose of the present study is to determine how effective this wire is as a work horse wire in patients in whom FFR is required.

The OptoWire may also have the advantage of less "drift" occuring during the procedure. Drift refers to the change in pressure due to issues related to the wire and measuring system, rather than a true change in pressure. All current FFR wire systems demonstrate some degree of drift requiring measuring pressure of the wire in the aorta after the procedure is completed to determine if, and to what extent, drift has occurred. Thus, a secondary aim of this study will determine the degree of drift.

In clinical practice, FFR is performed before, and often after, PCI. In a study of 574 patients treated at the Little Rock VA (IRB Study, #779601), teh investigators found that approximately 20% of angiographically optimized PCI still had an ischemic FFR. The investigators further found that this ischemic value could be improved by further treatments including balloon angioplasty and stenting. Thus, the secondary purpose is to measure FFR after successful PCI to ascertain the incidence of persistently ischemic FFR after optimized angiographic stenting to confirm the result from out previous study.

Statistical analysis

This study is descriptive. It will use means and standard deviation for continuous variables and prevalence or incidence in percentages as appropriate to show results. As there is no comparator group, comparative statistics will not be employed.

Research aspect of study

The research aspect of the study is limited to the systematic collection and analysis of data using the Opsens FFR wire with plan for publication. The other aspects of the study are considered part of routine clinical care. They include passage of FFR wire, measurement of FFR pre- and post-PCI, and performance of PCI itself.

Significance of study

A wire that can be used as a workhorse as well as be able to measure FFR would be of great value. The more effective and efficient is the FFR wire in not only measuring pre-PCI FFR but being able to be used for PCI and be stable and durable enough to be used for post-PCI optimization, the greater is the probability that this approach will be more generally adopted into clinical practice. Demonstration that the Opsens FFR wire is effective in this regard should further this goal.

The investigators previously demonstrated that 21% or about 1 in 5 patients had an ischemic FFR after satisfactory angiographic result. This study will confirm previous results or suggest either an over- or under-estimation of that incidence.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 10, 2019
Est. primary completion date December 10, 2019
Accepts healthy volunteers
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria:

Patients (age 18-89 years old) eligible and in whom the operator has performed FFR will be included to systematically evaluate the performance of the OptoWire FFR wire. A total of 1000 consecutive patients deemed to require FFR as part of clinical care will be included. It is felt that 1000 patients represent a reasonable sample size to study the OptoWire FFR wire handling characteristics, the primary endpoint of the study

Exclusion Criteria:

1. Not a candidate for FFR

2. Chronic total occlusion lesion

3. Hemodynamically unstable

4. Saphenous vein graft lesions -

Study Design


Intervention

Diagnostic Test:
Fractional Flow Reserve
This is a prospective data collection study for patients that have undergone FFR.

Locations

Country Name City State
United States John L. McClellan Memorial Veterans Hospital Little Rock Arkansas

Sponsors (1)

Lead Sponsor Collaborator
Central Arkansas Veterans Healthcare System

Country where clinical trial is conducted

United States, 

References & Publications (4)

Agarwal SK, Kasula S, Hacioglu Y, Ahmed Z, Uretsky BF, Hakeem A. Utilizing Post-Intervention Fractional Flow Reserve to Optimize Acute Results and the Relationship to Long-Term Outcomes. JACC Cardiovasc Interv. 2016 May 23;9(10):1022-31. doi: 10.1016/j.jcin.2016.01.046. — View Citation

Costa F, Ariotti S, Valgimigli M, Kolh P, Windecker S; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading? J Cardiovasc Transl Res. 2015 Jun;8(4):211-20. doi: 10.1007/s12265-015-9632-6. Epub 2015 May 19. Review. — View Citation

Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011 Dec 6;58(24):e44-122. doi: 10.1016/j.jacc.2011.08.007. Epub 2011 Nov 7. — View Citation

Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009 Jan 15;360(3):213-24. doi: 10.1056/NEJMoa0807611. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Opsens FFR Wire Performance Satisfactory performance is defined as the ability to perform the entire PCI plus measure FFR pre and post PCI with drift <0.05. Acute result at end of procedure
Secondary Incidence of Ischemic or Low Non-ischemic FFR post PCI requiring further intervention Acute result at end of procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions N/A

External Links